Abstract:The rapid development of a stereoselective route for CXCR7 antagonist ACT-1004-1239 was needed, as the large-scale chromatographic separation of enantiomers was not a viable option for a resupply campaign that targeted >30 kg of API. The key to success was the stereoselective reduction of a chiral enamine derived from inexpensive (S)-α-methylbenzylamine. The reduction showed good selectivity for the desired cis-3R,4S-isomer, and the pure diastereomer (d.r. >98:2) was isolated as its TFA salt. After removal of the ethylbenzyl group and amide coupling with 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid, the enantiopure cis-3R,4S-amide was isolated. The subsequent epimerization of the 3-position adjacent to the methyl ester turned out to be a formidable challenge, as the standard conditions with NaOMe led to the formation of a thermodynamic mixture of the cis and trans isomers (final ratio of ∼1:4). Therefore, a new procedure was developed in which the methyl ester was transesterified in situ to the isopropyl ester with KOiPr in iPrOH, followed by epimerization to the trans-iPr-ester (final cis:trans ratio 5:95). After saponification with aqueous KOH, the desired trans-3S,4S-acid was isolated in overall 76% yield. After amide coupling and Boc deprotection, the final reductive amination with cyclopropanecarboxaldehyde was also vastly improved. A novel NaBH(OAc)3 solution in DMSO was used for the reaction and cleanly provided the API with high purity after simple aqueous quench without the need for any solvent switches or aqueous workups. As a proof of concept, 240 g of API was produced in house with the novel stereoselective route, which was then also used to produce over 30 kg of GMP material at an external manufacturer for Phase 2 clinical studies.

Multigram Scale, Chiron-Based Synthesis of Sacubitril

Development of a multistep reaction cascade for the synthesis of a sacubitril precursor in continuous flow

Practical Synthesis of Macrobicyclic Thiolincosamines

Chemo-enzymatic Asymmetric Synthesis of S-citalopram by Lipase-Catalyzed Cyclic Resolution and Stereoinversion of Quaternary Stereogenic Center.

An Improved Process for Chiron Synthesis of the Atorvastatin Side Chain

NHC-Catalyzed Transition-Metal-Free Allylation of Aldehydes with MBH Carbonates and Their Michael Addition-Elimination-Cope Rearrangement Cascade: Facile Access to Sacubitril API

Development Of A Concise, Scalable Synthesis Of A Ccr1 Antagonist Utilizing A Continuous Flow Curtius Rearrangement

Development of a Scalable, Stereoselective Second-Generation Route for CXCR7 Antagonist ACT-1004-1239 via Chiral Enamine Reduction and a Novel Telescoped Sequence of Transesterification, cis -to- trans Epimerization, and Saponification

De Novo Synthesis of Chrysin in Saccharomyces cerevisiae

Structure-Unit-Based Total Synthesis of (-)-Sinulochmodin C

Gram-Scale Synthesis of the Fucose-Containing Fragments of Saccharomicins

A General and Scalable Method toward Enantioenriched C2-Substituted Azetidines Using Chiral tert -Butanesulfinamides

Development of a Large-Scale Asymmetric Process for Tert-Butanesulfinamide

Design and stereoselective preparation of a new class of chiral olefin metathesis catalysts and application to enantioselective synthesis of quebrachamine: catalyst development inspired by natural product synthesis.

Enantioselective construction of stereogenic-at-sulfur(IV) centres via catalytic acyl transfer sulfinylation

Scalable Synthesis of Antihistamines and Sensipar via Intensified Hydrogen Borrowing Methodology

Asymmetric Synthesis of Both Enantiomers of Dimethyl 2-Methylsuccinate by the Ene-Reductase-Catalyzed Reduction at High Substrate Concentration

Metabolic engineering of Saccharomyces cerevisiae for chelerythrine biosynthesis

10-Step Total Synthesis of Speradine C.

Engineering Saccharomyces cerevisiae for high-efficient production of ursolic acid via cofactor engineering and acetyl-CoA optimization

Regio‐ and Enantioselective Synthesis of Succinimides Bearing All‐carbon Quaternary Centers Using a Chiral Phenanthroline‐Pd Catalyst